MAIN DAY ONE

Innovation in the BioPharma Partnering LandscapeWEDOct 23, 2019

7:00 AM

Full Breakfast Buffet & Registration

8:05 AM

Welcome RemarksMatt MillmanLife Science Research DirectorBioNetwork 2019

8:15 AM

Chairperson’s Opening AddressJonathan GertlerManaging Partner & CEOBack Bay Life Science Advisors

8:30 AM

KEYNOTEShaping Innovation in a Changing Healthcare Landscape

Michal PremingerHead, Johnson & Johnson Innovation, East North AmericaJohnson & Johnson

9:00 AM

KEYNOTEGenomic Prediction of Complex Traits and Disease Risks via AI and Large Genomic Datasets

Steve HsuSVP, Office of Research and InnovationMichigan State University

Start BioNetwork with an opportunity to immediately meet attendees with the same therapeutic interest as you. Sharing current challenges & opportunities and get a jump start on identifying which individuals to meet with.

Tables & Discussion Leaders include:

9:30 AM

MIMOSA THERAPEUTIC AREA ROUNDTABLE DISCUSSIONS

1. OncologyAshim SubedeeProgram DirectorNCI Small Business Innovation Research (SBIR) Development Center

2. ImmunologyMichael JohnsonVP, Business DevelopmentEli Lilly

3. NeuroscienceRobert BagdorfVP, Worldwide Business DevelopmentPfizer

4. Rare & Orphan DiseasesJoe WhalenSVP, BD, & Alliance ManagementHorizon Pharma

Jordan ZwickSenior Director, StrategySalix Pharmaceuticals

7. Immuno-oncology

5. Pain

8. Infectious Diseases

6. Endocrinology

10:00 AM

Morning Refreshment Break & Partnering Opens

This talk is divided into two parts. The first gives an overview of the rapidly advancing area of genomic prediction of disease risks using polygenic scores. We can now identify risk outliers (e.g., with 5 or 10

times normal risk) for about 20 common disease conditions, ranging from diabetes to heart diseases to breast cancer, using inexpensive SNP genotypes (i.e., as offered by 23andMe). We can also predict some complex quantitative traits (e.g., adult height with accuracy of few cm, using ~20k SNPs).

This talk will discuss application of these results in precision medicine as well as embryo selection in IVF, and give some details concerning genetic architecture.

The second part covers the AI/ML used to build these predictors, with an emphasis on “sparse learning” and phase transitions in high dimensional statistics.

Healthcare has been undergoing dramatic changes due to a congruence of three trends: the explosion of scientific knowledge and previously unimaginable enabling technologies; the empowerment and broad use of self-quantification for health information by consumers and the exploitation of big data sets by industry to drive

new healthcare related insights; and, finally, pressures from and on the healthcare system to adopt new models, including stronger focus on early detection and prevention. In this session, we will hear how Johnson & Johnson harnesses its expertise in pharma, medical device and consumer products to transform the innovation landscape to meet patient, consumer, and market needs in this new reality.

www.asdevents.com - www.asdevents.com/event.asp?id=21688

MAIN DAY ONE

Innovation in the BioPharma Partnering LandscapeWEDOct 23, 2019

There is a mad dash to utilize innovative technology for drug development and investment with the hopes for increased speed & efficiency. However, a knowledge gap exists on the availability and viability of these technologies. This panel discussion will share the perspectives from fledgling technology innovators and industry representatives on what boxes must be checked off in order to be successful when partnering with high technology.

10:30 AM

PANELThe Colliding Worlds of High Technology & Life Sciences

Jennifer LeedsHead, West Coast Search and EvaluationNovartis

Lisa ConteFounder, President and Chief Executive OfficerJaguar Health

Isaac BrightCo-Founder and Chief Executive OfficerRubrYc Therapeutics

Jeff EltonChief Executive OfficerConcerto Health AI

Ron AlfaSenior Vice President of Translational Discovery & Chief EvangelistRecursion Pharma

11:00 AM

Biotech Spotlight Session: Jaguar Health

11:15 AM

Biotech Spotlight Session: RubrYc Therapeutics

10:00 AM

1:1 Partnering

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis.

The highly competitive immuno-oncology market is poised for massive growth for all the right reasons. As opposed to conventional therapies like radiation, immunotherapy has shown to have low-toxicity, higher approval rates and subsequently rapid clinical adoption. This panel will discuss the current standing and opportunities in the immunotherapy market as well as enabling deal structures that best allow promising candidates to get to market.

RubrYc Therapeutics is a biotechnology company that integrates chemistry and computation to decode therapeutically significant protein interfaces, revolutionizing the discovery of antibody-based drugs.

11:30 AM

PANELThe Future of Immuno-Oncology Deal Making

Michael JohnsonVP, Business DevelopmentEli Lilly

Melissa FitzgeraldHead of Oncology Search & EvaluationHalozyme Therapeutics

Syed KazmiGlobal Head, Business Development & Licensing, OncologyNovartis

12:00 PM

Biotech Spotlight Sessions

12:30 PM

Networking Lunch in the Courtyard

To achieve success, the right partnership “fit” is critical but how can stakeholders best identify a strong cultural match while navigating the current landscape of both market and company-specific challenges? Even in the strongest partnerships, a variety of hurdles can arise that terminate a deal. The art of due diligence to address financial resources, manufacturing capabilities, regulatory consideration and many more must be addressed properly to ensure contractual deliverables that nurture success. This session will review the approach to due diligence with specific how-to’s and how-nots shared.

1:30 PM

PANELMastering the Science of Due Diligence

Robert BagdorfVP, Worldwide Business DevelopmentPfizer

Wesley GalambUS Lead, Business Development & InnovationNovo Nordisk

Vanitha SekarExecutive Director, Business Development & LicensingMerck Research Labs

Jump to www.asdevents.com - www.asdevents.com/event.asp?id=21688

MAIN DAY ONE

Innovation in the BioPharma Partnering LandscapeWEDOct 23, 2019

1:30 PM

1:1 Partnering

2:00 PM

Biotech Spotlights

5:00 PM

Veranda Sunset Reception Overlooking the Laguna Hills

6:00 PM

End of BioNetwork Day One

Laszlo KissExecutive Director, WRD and PrincipalPfizer Ventures

The investment and funding landscape has evolved rapidly and deal structures have progressed far from the one-size-fits-all approach. This session will examine some creative deals including co-development and co-promotional rights. Lessons will be shared from unconventional deals that have taken place in the past couple of years. Learn how the biopharma funding landscape is still evolving and how biotechs can take advantage of the current funding environment.

2:30 PM

PANELCreative Strategies in Biopharma Funding

Neena KadabaDirector, ScienceQuark Ventures

This session will discuss:

� History of how the deal came into existence

� What each partner brings to the table

� What specifically TNB-383B is, and why working on this program collaboratively was an attractive proposition to both parties

4:30 PM

DEAL SPOTLIGHTTales from the Trenches: A Brief History of how Teneobio and Abbvie Came Together to Become Partners in the Development of TNB-383B, A Novel Bispecific T Cell Engager for Multiple Myeloma

Niels EmmerichVP, Global Head Search & EvaluationAbbVie

Roland BuelowCEOTeneoBio

� How this deal augments AbbVie’s Oncology pipeline

� What value and differentiated value proposition both companies believe TNB-383B could bring to patients

Jump to

3:00 PM

Biotech Spotlights

3:30 PM

Afternoon Refreshment Break

4:00 PM

Biotech Spotlights

www.asdevents.com - www.asdevents.com/event.asp?id=21688

MAIN DAY TWO

Opportunities, Challenges & Emerging Trends in Pharma Deal-makingTHUOct 24, 2019

7:30 AM

Full Breakfast Buffet & Registration

7:30 AM

Women in Biotech Breakfast Boardroom

Moderated by: Nina KjellsonGeneral PartnerCanaan Partners

8:25 AM

Welcome Remarks

Matt MillmanLife Science Research DirectorBioNetwork 2019

8:30 AM

Chairperson’s Opening Address

As the leader and owner of the formulary management and procurement function for United Health Group’s PBM,

OptumRx, Kent Rogers knows first-hand that the industry lacks a fundamental understanding of the payer landscape --

who payers are, what they do, and most importantly, what drugmakers need to know. Now that the Trump administration is proposing broad sweeping changes to the construct of how the supply chain operates, it is more important than ever that an understanding of where we are informs us of where we may be headed.

Kent’s talk will address:

� How do we change the focus from pricing and rebates to value? Is it scalable and could it affect pharma’s pricing decisions?

� Will the proposal to remove barriers of “best-price” when it comes to implementing value-based agreements with pharma encourage pharma to contract more readily in that space?

� Would the proposal to remove 100% of AMP deter price increases?

� With the proposed changes to the Competitive Acquisition Program in Medicare Part B, if the incentives to profit on the purchase and administration

8:45 AM

KEYNOTEAnnual Update on the Pricing & Reimbursement Landscape

Kent RogersSVP, Industry RelationsOptumRx

Moderated by: Nina KjellsonGeneral PartnerCanaan Partners

Pablo CagnoniCEORubius (and BoD member, CRISPR)

Peter OlagunjuVP, Global Patient Operationsbluebird bio

Amy DuRossCo-founder and CEOVineti

Lawrence KleinChief Business OfficerCRISPR Therapeutics

Kosta KleymanCAR-T Marketing Launch & Strategy LeaderCelgene/Juno

of oncology medications are neutralized – what will be the impact?

� What impact would advertising list prices have in the marketplace with providers or patients?

Development of gene and cell therapies come with huge upsides but also at a steep price due to the complexity and time needed for the development process. But as approvals for these therapies become more prevalent, and the value of this field rapidly rises, new methods of financing and supporting pioneering gene and cell therapies through their development pains are on the rise. This session will examine how new models and partnerships are leveraging the learning curve and where investment and financing opportunities can be found.

9:15 AM

PANEL PART 1:Getting Gene & Cell Therapies from Bench to Bedside: What Do Successful Models and Partnerships Really Look Like?

9:45 AM

Biotech Spotlights

Jump to www.asdevents.com - www.asdevents.com/event.asp?id=21688

MAIN DAY TWO

Opportunities, Challenges & Emerging Trends in Pharma Deal-makingTHUOct 24, 2019

12:15 PM

Networking Luncheon

1:15 PM

DEAL SPOTLIGHTDaiichi Sankyo and AstraZeneca Global Development and Commercialization Collaboration for Daiichi Sankyo’s HER2 Targeting Antibody Drug Conjugate [Fam-] Trastuzumab Deruxtecan (DS-8201)

Chris SheldonHead of Oncology Search and EvaluationAstraZeneca

Jonathan YorkVice President, Global Business DevelopmentDaiichi Sankyo

Judith HaskoPartnerLatham & Watkins

11:45 AM

PANELCurrent Trends in Strategic Corporate Ventures

David MorrisManaging DirectorNovartis Venture Fund

Moderated by: Michael O’donnellPartnerMorrison Foerster

KT MoortgatDirectorAbbVie Ventures

Jak KnowlesVice President, Venture InvestmentsBayer

9:45 AM

1:1 Partnering

11:15 AM

Biotech Spotlights

10:15 AM

Morning Refreshment Break

10:45 AM

PART 2:Getting Gene & Cell Therapies from Bench to Bedside: What Do Successful Models and Partnerships Really Look Like?

Brinda BalakrishnanGroup Vice President, Business and Corporate DevelopmentBioMarin Pharmaceuticals

Nouhad HusseiniVice President, Head of Business DevelopmentRegeneron Pharmaceuticals

Don FrailSVP, Research, External Science & InnovationAllergan

Jump to

This session will feature the perspectives of various corporate venture capital firms discussing the advantages of big pharma including a venture capital arm into their overall funding capability. What are the specific benefits of working with corporate VCs in your capital structure and are there differing approaches between corporate and traditional VCs when looking for investment opportunities.

www.asdevents.com - www.asdevents.com/event.asp?id=21688

MAIN DAY TWO

Opportunities, Challenges & Emerging Trends in Pharma Deal-makingTHUOct 24, 2019

2:45 PM

Biotech Spotlights

3:15 PM

Afternoon Refreshment Break

3:45 PM

PANELEvolving Trends in Open Innovation and Role of Academia - Recipes for Partnership Success

Abhijit BanerjeeSenior Director, Business DevelopmentOregon Health & Science University

Alan KoncarevicDirector, Industry Relations; Head, Strategic AlliancesUniversity of Chicago

Vasiliki AnestSenior Director, Business Development and Industry RelationsMESH (Medicine, Engineering, Sciences, and Humanities) Academy at the Keck School of Medicine USC

Investments made in seed and Series A for biotech companies has significantly grown due to the possibilities therapies have at this stage but also the opportunities as a more strategic partner. This approach also allows investors to observe disease states more thoroughly as well as the innovation process behind the therapies. Innovators also often times benefit from the financial and process know-how early stage investors can bring to the table. This session will examine these trends and provide instances of how early-stage partnerships can be crucial for getting therapies to market.

2:15 PM

PANELEarly-Stage Collaboration to Improve the Development and Commercial Process

Jordan ZwickSenior Director, StrategySalix Pharmaceuticals

Joe WhalenSVP, BD, & Alliance ManagementHorizon Pharma

1:15 PM

1:1 Partnering

1:45 PM

Biotech Spotlights

Jump to www.asdevents.com - www.asdevents.com/event.asp?id=21688

On paper, a potential deal can look significantly different then in practice. The wrong partner can put pressure on operational aptitude and stop a therapy from getting to market. This panel will examine how the right partnership can be developed early on and drive creativity in how innovations can get to patients. It will also examine how different types of potential partners can raise specific hurdles and what alliance management professionals look for in the right collaboration.

4:15 PM

PANELInvolving Alliance Management Early in Deal Discussions and Interactions

Monica VizianoExecutive Director, Alliance ManagementGilead

Anna MaroneyVice President, Corporate Strategy Office, Head, Alliance ManagementAbbVie

4:45 PM

Casino Night Evening Reception

5:45 PM

End of Day Two

MAIN DAY TWO

Opportunities, Challenges & Emerging Trends in Pharma Deal-makingTHUOct 24, 2019

Jump to www.asdevents.com - www.asdevents.com/event.asp?id=21688

PartneringMade Easy

OCTOBER 23-25, 2019THE RITZ-CARLTON

LAGUNA NIGUEL, CA

MAIN DAY THREE

Networking & Partnering OpportunitiesFRIOct 25, 2019

8:00 AM

Breakfast & Partnering Opens

12:00 PM

BioNetwork 2019 Concludes

9:00 AM

CLSA Executive Forum

This invitation-only forum will convene senior executives from biotech and biopharma companies to discuss ideas, advice, and key success factors to get treatments to patients faster. Join us to hear the findings from the recent market reports and participate in a series of curated discussions:

� Investment Landscape: Dealmaker strategy and objectives

� Drivers of change in clinical trials

� Regulatory Landscape: Disrupters creating regulatory flexibility

� Patients, Pricing, and Payors: Ensuring patient value and stakeholder value are aligned

� Drivers of Launch Success

Jump to www.asdevents.com - www.asdevents.com/event.asp?id=21688